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Background: Silymarin derived from the milk thistle plant “Silybum marianum” is composed of four major
flavonolignans. Clinical as well as experimental studies indicate hepatoprotective effects of silymarin. However, the
underlying mechanisms are only incompletely understood.
The aim of this study was to assess the effect of oral administration of a defined silymarin extract in the model of
acute carbon tetrachloride (CCl4) induced liver injury.
Methods: A single dose of a silymarin extract (SE; 20 or 100 mg/kg body weight) was given to rats by oral gavage.
Subsequently, rats were injected with a single dose of CCl4 (2 ml/kg body weight).
Results: After 24h, analysis of liver to body weight ratio, serum levels of transaminases and histological analysis
revealed a marked liver damage which was inhibited by SE in a dose dependent manner. CCl4-induced expressions of
pro-inflammatory and pro-fibrogenic genes were significantly reduced in SE treated rats. Molecular analysis revealed
that SE reduced the expression of the pro-inflammatory chemokine MCP-1, the pro-fibrogenic cytokine TGF-beta as well
as collagen I in isolated human hepatic stellate cells (HSC), which are the key effector cells of hepatic fibrosis.
Conclusion: Oral administration of the tested silymarin extract inhibited hepatocellular damage in a model of acute liver
injury. Moreover, we newly found that the silymarin extract had direct effects on pro-inflammatory and pro-fibrogenic
gene expression in HSCs in vitro. This indicates that direct effects on HSC also contribute to the in vivo hepatoprotective
effects of silymarin, and further promote its potential as anti-fibrogenic agent also in chronic liver disease.
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Silymarin (Silybum marianum) is a herbal medicinal prod-
uct constituting of a mixture of four flavonolignan isomers,
namely silybin, isosilybin, silydianin and silychristin with an
empirical formula C25H22O10. Silybin is the major and most
active component and represents about 60-70 % of sily-
marin, followed by silychristin (20 %), silydianin (10 %), and
isosilybin (5 %). Several studies have shown silymarin as
hepatoprotective herbal drug [5, 15, 18].
One of the models most frequently studied in the context
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provided the original work is properly credited(CCl4)-induced hepatotoxicity. It is known that CCl4-
induced hepatotoxicity is originated from its highly lethal
reactive metabolites such as trichloromethyl (CCl3•) and
peroxy trichloromethyl (CCl3OO•) radicals, which are gen-
erated by microsomal cytochrome P450 (CYP) in mamma-
lian liver [19]. CCl3• can react with a variety of biologically
important cellular molecules, such as proteins, lipids, and
nucleic acids. This causes impairments of liver function
which can affect crucial cellular processes leading to hepa-
tocellular injury [20, 27]. It has been shown that silymarin
protected against the CCl4-induced hepatotoxicity through
scavenging free radicals and reactive oxygen species
[13, 22]. Furthermore, anti-inflammatory and anti-fibrotic
properties have been described (reviewed in [1]). While a
few studies have investigated the effectiveness of silymarinle distributed under the terms of the Creative Commons Attribution License
hich permits unrestricted use, distribution, and reproduction in any medium,
.
Mahli et al. Clinical Phytoscience  (2015) 1:5 Page 2 of 8in a chronic CCl4 model upon oral application and with
regards to the fibrogenic reaction [6, 16]. We for the first
time studied the acute effects of orally administered milk
thistle extract on early events in fibrosis development.
The activation of HSC is the key event of hepatic fibrosis.
The activation of these cells occurs in response to hepatic
injury in chronic liver disease. Upon HSC activation, HSC
change their phenotype into myofibroblast- like cells with
increased production of extracellular matrix (ECM) compo-
nents such as collagen type I [8, 17]. Furthermore, activated
HSC contribute to hepatic inflammation in response to
acute as well as chronic liver injury by synthesizing various
cytokines and chemokines such as monocyte chemoattract-
ant protein-1 (MCP-1) [24].
The aim of this study was to evaluate the effect of a
defined extract of silymarin (SE; Silimarit®) against CCl4-
induced hepatocellular damage as well as on pro-
inflammatory and pro-fibrogenic gene expression. Further,
we performed in vitro analysis in which we investigated the
effects of the same extract on the gene expression of acti-
vated human HSC. We demonstrated that the application
of the extract protected from the CCl4-induced hepatic in-
jury in a dose dependent manner. Furthermore, our data
indicate that direct effects on activated HSC contributed to
the hepatoprotective effects of the silymarin extract.
Methods
Chemicals
Carbon tetrachloride (CCl4) and corn oil were obtained
from Sigma Pharmaceuticals (Hamburg, Germany). For
treatment of animals, Silimarit® dry extract (SE, milk thistle
extract compliant with Pharmacopoea Europaea, Bionorica
SE, Neumarkt, Germany) was used. For dissolution of ex-
tracts, an aqueous solution of methyl hydroxypropyl cellu-
lose (MHPC, 0.5 %, methocel™ E4M prem) was prepared.
Isolation and stimulation of activated hepatic stellate cells
Hepatic stellate cells (HSC) were isolated from liver
specimens using a modified 2-step EGTA/collagenase
perfusion procedure [28]. Subsequently, HSC were puri-
fied by arabinogalactan gradient ultracentrifugation [11].
HSC were cultured in Dulbecco’s modified Eagle
medium (DMEM) supplemented with 10 % FCS, 100
IU/mL penicillin, and 100 μg/mL streptomycin in a 95 %
air/5 % CO2-humidified atmosphere. For induction of
in vitro activation, freshly isolated HSC were seeded on
uncoated plastic dishes for two weeks [11].
Animals and model of acute liver injury
Sprague-Dawley rats were obtained from Charles River La-
boratories (Sulzfeld, Germany). Animals were housed in the
animal facilities at the University of Regensburg and fed
with a standard diet. For in vivo application SE was sus-
pended in 0.5 % solution of MHPC and given to six weeksold male rats at a single dose of 20 or 100 mg/kg body
weight (BW) by oral gavage (n = 4-5/group). Control rats
(n = 5) received solvent MHPC by oral gavage. After 3 h,
rats were injected i.p with a single dose of carbon tetra-
chloride (CCl4) (1 ml/kg BW.; 1:1, v/v in corn oil) or an
equal volume of the solvent (corn oil). 24 h after CCl4 injec-
tion, rats were sacrificed by heart puncture under deep keta-
mine/xylazine (2:1) anesthesia and liver tissue and blood
samples were collected for further analysis. Livers and blood
from HPMC/corn oil treated animals served as controls.
Histology
For histological analysis liver tissue specimens were fixed
for 24 h in 4 % formalin at room temperature, dehy-
drated by graded ethanol and embedded in paraffin. Tis-
sue sections (thickness 5 μm) were deparaffinized with
xylene and stained with hematoxylin and eosin (H&E).
Hepatic staining for Ki67 (a marker of regeneration) was
examined using a standard immunohistochemical pro-
cedure as described [3]. The number of ballooning cells
or Ki67-positive hepatocytes was counted in 4 randomly
selected areas on each section.
Quantitative real-time-PCR analysis
RNA isolation from hepatic tissues or cultured cells and
reverse transcription were performed as described [10].
Quantitative real-time-PCR was performed applying
LightCycler technology (Roche) [10] using specific sets
of QuantiTect Primer Assays according to the manu-
facturer's instructions (Qiagen, Hilden, Germany). Amp-
lification of cDNA derived from 18s rRNA (for: 5'-
TGATTAAGTCCCTGCCCTTTGT; rev: 5'-GATCCG
AGGGCCTCACTAAAC) was used for normalization.
Analysis of hepatic collagen levels
Liver specimens were subjected to analysis of acid-
pepsin soluble collagen using the Sircol Collagen Assay
(Biocolor, Carrickfergus, UK) according to the manufac-
turer’s instructions.
Quantification MCP-1 protein levels
MCP-1 protein levels in cell culture supernatant were
analyzed using the Quantikine Human MCP-1 Immuno-
assay (R&D systems, Wiesbaden, Germany) according to
manufacturer’s instructions.
Statistical analysis
Values are presented as mean ± SEM. Comparison be-
tween groups was made using the Student’s unpaired
t-test. A p value <0.05 was considered statistically signifi-
cant. All calculations were performed using the statis-
tical computer package GraphPad Prism version 4.00 for
Windows (GraphPad Software, San Diego, USA).
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Effect of the silymarin extract (SE) on hepatocellular
damage in the model of acute CCl4-induced liver injury
24 h after CCl4-induced toxic liver injury was initiated,
the liver to body weight ratio was significantly elevated
in CCl4-treated rats while this increase was abrogated in
SE- treated groups (Fig. 1a). The increase of liver to
body weight ratio in CCl4-treated rats was mainly caused
by a significant loss in the body weight which was less
prominent in SE-treated rats (data not shown). Also
macroscopically, livers of CCl4-treated rats appeared lar-
ger and with a pale and irregular surface indicative of se-
vere hepatocellular damage; representative images are
depicted in Fig. 1b. Histopathological analysis confirmed
large areas of necrotic tissue and a significant number of
ballooning hepatocytes in the livers of CCl4-treated rats
which was less prominent in SE-treated animals (Fig. 1c).
CCl4-induced macroscopic and histopathological changes
were attenuated in SE-treated animals (Fig. 1b and c). In
normal liver, almost no hepatic cells showed Ki67 staining,
a marker of cellular proliferation, while Ki67 immuno-
signals were markedly enhanced in response to CCl4-
treatment reflecting repair of considerable liver damage
(Fig. 1d). SE-treated rats showed significantly less Ki67
positive liver cells indicating reduced hepatocellular dam-
age (Fig. 1d). Hepatocellular injury in the CCl4 groups was
also reflected by a marked increase of serum transami-
nases compared to the control group, but this increase
was less pronounced in SE-treated rats (Fig. 1e). Although
the differences in serum transaminases did not reach the
level of significance they point to the overall picture show-
ing a hepatoprotective effect of SE in the model of acute
CCl4-induced liver injury.
Effect of the silymarin extract (SE) on pro-inflammatory
and pro-fibrogenic gene expression in the model of acute
CCl4-induced liver injury
Heme oxygenase-1 (HMOX-1) is an essential enzyme in
the heme catabolism, which is induced by oxidative
stress. Quantitative real-time PCR revealed a significant
induction of the HMOX-1 expression in response to
CCl4 treatment (Fig. 2a). This increase in HMOX-1 was
dose dependently abrogated by SE indicative for reduced
oxidative stress (Fig. 2a).
Oxidative stress is a well-known inducer of a pro-
inflammatory reactions, and in line with this, we observed a
significant induction of hepatic mRNA expression levels of
tumor necrosis factor (TNF) and interleukin-1 beta (IL-1ß)
in CCl4-injured livers (Fig. 2b and c). The induction of TNF
and IL-1ß was significantly reduced by SE in a dose
dependent manner (Fig. 2b and c).
Moreover, the expression of monocyte chemo-attractant
protein-1 (MCP-1) was markedly increased in CCl4-in-
jured livers (Fig. 2d). In rats which had received SE thisMCP-1 induction was significantly reduced (Fig. 2d).
While TNF and IL-1ß are mainly expressed by resident
and infiltrating immune cells in an injured liver hepatic
MCP-1 expression levels are dependent on activated HSC
[24]. HSC activation is recognized as a central event in the
development of hepatic fibrosis and lastly, cirrhosis.
Transforming growth factor beta (TGF-β) is also expressed
by activated HSC and one of the most potent pro-
fibrogenic cytokines in liver disease. We detected a strong
induction of TGF-ß in CCl4-injured livers, and this induc-
tion was significantly reduced by SE in a dose dependent
manner (Fig. 2e). Analysis of hepatic collagen content re-
vealed only a slight induction of collagen content after 24 h
CCl4-treatment (Fig. 2f), which can be explained by the fact
that fibrosis is a time-dependent process and repeated
CCl4-applications are required to induce significant hepatic
collagen accumulation over time. Notably, the slight in-
crease of hepatic collagen content in response to CCl4-
treatment was not observed in SE-treated rats (Fig. 2f). To-
gether, these data indicate that SE inhibits the pro-
inflammatory and pro-fibrogenic response to CCl4-induced
liver injury. Because it is known that biotransformation of
CCl4 is mainly mediated by CYP2E1 [27, 29], we further
analyzed the hepatic expression levels of this cytochrome
and found a marked decrease in response to CCl4 treat-
ment. Interestingly, this decrease was reduced in SE treated
rats (Fig. 2g). It can only be speculated whether this less
pronounced downregulation of CYP2E1 affected the CCl4-
metabolisms. In any case, it appears that SE exhibited its
hepatoprotective effects in response to acute CCl4-injury at
different levels.Effect of the silymarin extract (SE) on pro-inflammatory
and pro-fibrogenic gene expression in activated hepatic
stellate cells
The in vivo data indicated that SE affected pro-
inflammatory and pro-fibrogenic gene expression in HSC.
However, they did not allow the differentiation, whether
this is an indirect effect via reduced tissue damage and in-
flammation or whether SE exhibits also a direct effect on
HSC. To address this question, we stimulated primary ac-
tivated human HSC with SE in vitro. Interestingly, we
found that SE significantly reduced the mRNA expression
of MCP-1 and TGF-beta in HSC in a dose dependent
manner (Fig. 3a,b). Analysis of MCP-1 protein levels in
the cell culture supernatants confirmed this result on the
protein level (Fig. 3c). Moreover, expression of collagen-I,
the predominant extracellular matrix protein in fibrotic
human tissues, was significantly impaired by SE stimu-
lation of activated HSCs in vitro (Fig. 3d). Together,
these findings indicated that SE directly affects pro-
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Fig. 1 (See legend on next page.)
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Fig. 1 Effect of silymarin (SE) on hepatocellular damage in CCl4- induced liver injury. Rats were treated with MHPC (control) or silymarin (SE) at a
single dose of 20 mg/kg BW (SE-20) or 100 mg/kg BW (SE-100) by oral gavage. After 3 h rats were injected with a single dose of CCl4 or the
equal volume of vehicle (control). 24h after CCl4 injection, rats were sacrificed. a Liver-to-body -weight-ratio. b Representative macroscopic images
of livers from the four treatment groups. c H&E staining of liver tissue (Magnification 20x) (left panel); quantification of ballooning hepatocytes in
hepatic tissues (right panel). d Representative images of Ki67 stained liver tissues (left panel); quantification of Ki67 positive hepatocytes in hepatic
tissues (right panel). e AST and ALT serum levels. (*: p < 0.05)
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The aim of this study was to assess the effect of oral ad-
ministration of a Silimarit® dry extract (SE) in the model
of acute CCl4-induced liver injury. Our results reveal
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Fig. 2 Effect of silymarin (SE) on the pro-inflammatory and pro-fibrogenic r
(control) or silymarin (SE) at a single dose of 20 mg/kg BW (SE-20) or 100 m
single dose of CCl4 or the equivalent volume of vehicle (control). 24h after
(a) HMOX-1 (b) TNF (c) IL1-ß (d) MCP-1 and (e) TGFß1 by quantitative RT-P
mRNA levels of CYP2E1 by quantitative RT-PCR. (*: p < 0.05)reduced pro-inflammatory and pro-fibrogenic gene ex-
pression. Oxidative stress due to CCl4-induced free rad-
ical production is one of the main mechanism by which
hepatocellular damage is induced in this model [12, 26].
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esponse in CCl4- induced liver injury. Rats were treated with MHPC
g/kg BW (SE-100) by oral gavage. After 3 h rats were injected with a
CCl4 injection, rats were sacrificed. Analysis of hepatic mRNA levels of





















































































Fig 3 Effect of the silymarin extract (SE) on pro-inflammatory and pro-fibrogenic gene expression in activated hepatic stellate cells (HSC). Primary
activated human HSC were stimulated in vitro for 24 h with SE in the indicated doses. a Analysis of mRNA levels of MCP-1, b TGFß1 and d Coll-I
by quantitative RT PCR. c Analysis of MCP-1 protein levels in the cell culture supernatant by ELISA. (*: p < 0.05)
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indicating reduced ROS formation as one mechanism by
which the hepatoprotective effect of the extract was me-
diated. Moreover, we found that SE treatment inhibited
the CCl4-induced hepatic TNF and IL-1ß expression in a
dose dependent manner which indicates reduced activa-
tion of Kupffer cells, the resident macrophages in the
liver, and less hepatic immune cell infiltration, respect-
ively. While TNF and IL-1ß are mainly expressed by
resident and infiltrating immune cells in an injured liver,
activated HSC contribute to hepatic MCP-1 expression
levels [24]. HSC activation is recognized as a central
event in the development of hepatic fibrosis and occurs
early in response to liver injury. Consequently, in the
model of acute CCl4-induced liver injury, HSC activation
has also been described as a crucial event by us and
others [25, 30]. Thus, reduced MCP-1 expression indicatesattenuation of liver injury after SE treatment. Upon hepatic
injury, HSC transform in an activated myofibroblast-like
cell type that is responsible for the excessive hepatic matrix
deposition in chronically damaged livers [8]. Transforming
growth factor beta (TGF-β) that is one of the most potent
pro-fibrogenic cytokines in liver disease is expressed by
activated HSC. TGF-β leads to an autocrine induction of
fibrogenic gene expression in HSC. SE treatment reduced
the CCl4-induced expression of TGF-β and collagen-I
which play crucial roles in liver fibrosis also in the CCl4
model [6, 7, 9, 16]. In our study, a remarkable decrease
of pro-fibrogenic and pro-inflammatory mRNAs was ob-
served, leading to the conclusion that the used silymarin
extract has protective effects on the formation of fibrosis
after acute liver injury induced by CCl4. These findings add
to the results of other studies showing reduced fibrosis in
injured liver tissue after silymarin treatment in chronic
Mahli et al. Clinical Phytoscience  (2015) 1:5 Page 7 of 8models of liver injury [2, 4, 14, 21, 23]. The protective role
of silymarin extract on early stages of fibrosis and liver
damage – as shown in this study – may also be relevant
in chronic liver disease. In a recent study Shaker and co-
workers demonstrated antifibrotic effects of a milk thistle
preparation and chemotherapeutic agents in chronic thioa-
cetamide (TAA)-induced liver injury. Although, the chem-
ical agents showed a profound anti-fibrotic potential, they
exhibited marked toxicity on hepatocytes. The advantage of
milk thistle treatment was that no toxic side effects on the
liver were observed [21]. Also in our study we did not
observe any negative side effects in SE-treated rats (data
not shown).
In humans as well as rodents the biotransformation of
CCl4 is mainly mediated by CYP2E1 and very marginally
by other CYPs (CYP2B and CYP3A) (reviewed in [27]).
Accordingly, CYP2E1 knockout mice are resistant to
CCl4 hepatotoxicity [29]. A recent study conducted with
guinea pigs (Cavia porcellus) showed increased hepatic
CYP2E1 expression in response to chronic alcohol
administration, while silymarin supplementation signi-
ficantly reduced this induction in comparison with
alcohol abstention group [2]. Here, we found that CCl4-
treatment caused a considerable decrease of hepatic
CYP2E1 expression, which was in line with a previous
study of Wong et al. [29]. Interestingly, the inhibitory
CCl4-effect on CYP2E1 expression was alleviated by SE-
treatment. These findings indicate that silymarin has a
modulating effect on hepatic CYP2E1 expression, which
can be altered by different hepatotoxins. Together, the
hepatoprotective effects and anti-fibrotic effect of SE
combined with the absence of toxicity makes it a good
candidate for further clinical investigations.
Importantly, our in vitro studies in primary human
HSC revealed that SE directly affects the expression of
pro-fibrogenic factors in HSC. These data indicate that
direct effects of the SE on HSC also contribute to the
hepatoprotective effect of SE in vivo. With regards to the
effect of SE on HSC and pro-fibrogenic gene expression,
respectively, it has to be noted that we applied the SE
orally in our study. After oral administration peak levels
of Silibinin, a major component of SE, are reached in
liver, lung, and stomach [31].
Conclusions
In conclusion, we found that the silymarin extract stud-
ied exhibited profound hepatoprotective effects in a
model of acute liver injury via different mechanisms.
Particularly, the inhibitory effects on fibrogenic factors
in this model as well as the direct anti-fibrogenic effects
of the extract on human HSC in vitro further indicate
the potential of this natural compound in the prevention
and treatment of hepatic fibrosis in patients with
(chronic) liver disease.Abbreviations
SE: Silymarin extract; CCl4: Tetra-carbon chloride; HSCs: Hepatic Stellate Cells.
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